We are pleased to announce the appointment of Victoria Sharpe as the new Managing Director of Exstent Limited. Victoria is a Chartered Engineer with a wealth of experience in the medical device industry and will lead the company through the next phase of its growth.
On 8 September 2020, Tal Golesworthy and Duke Cameron, MD presented a PEARS project update at The Marfan Foundation’s E-Summit.
You can watch the presentation below or on YouTube.
The Brisbane-based Courier-Mail carries a three page article describing how a patient with Marfan syndrome became the first to undergo repair to her dilated aortic root during pregnancy. The ability to perform PEARS surgery without the use of cardiopulmonary bypass reduced the risk to her unborn child. Five months later the patient gave birth to her healthy daughter.
The July issue of the British Journal of Cardiology carries a report on a multicentre study of 117 consecutive patients who received ExoVasc mesh implants for aortic root aneurysm from 2004 to 2017. The report concludes that the operation achieves the objectives of valve-sparing root replacement, and it is seen as a low-risk conservative operation which is complementary to more invasive procedures, such as valve sparing root replacement or total root replacement.
The paper may be viewed on-line at: http://dx.doi.org/10.5837/bjc.2020.022
On 15 November 2019 an ExoVasc PEARS surgical workshop was held in Prague with presentations from four UK surgeons and Czech surgeons and cardiologists who are involved with the PEARS programme. Clinical data was presented as well as case reports on ExoVasc PEARS recipients. At the end of the workshop, a live questionnaire was run concerning various technical aspects of the manufacture and implantation of the ExoVasc.
Videos of the presentations are available in the Surgical Information section of this website.
Exstent participated in the 33rd Annual Meeting of the European Association for Cardio-Thoracic Surgery, which took place in Lisbon, Portugal, 3-5 October 2019. The company also had a stand at the associated exhibition.
The 7 News channel in Australia reports on the introduction of the ExoVasc PEARS procedure at the Prince Charles Hospital in Brisbane in which surgeon Olivia Williams describes the PEARS procedure as ‘one of the most important advancements to have occurred in cardiac surgery over the last couple of decades.’
You can watch the video by clicking on the image below.
On Friday 24 May 2019, Tal Golesworthy celebrated the 15th anniversary of receiving his ExoVasc® Personalised External Aortic Root Support.
His aorta remains dimensionally stable and fully functional without aortic regurgitation, aortic dissection, aortic rupture, or the need for any form of drug intervention.
Since Tal’s implant in 2004, PEARS has successfully treated asymptomatic aortic dilation in 210 patients with Marfan Syndrome, Loeys-Dietz Syndrome, Bicuspid Aortic Valve Disease and various other idiopathic diseases. There are 657 patient-years’ post-operative experience and four female patients have had five uneventful pregnancies and deliveries. PEARS surgery is offered by 23 surgical centres in Ireland, UK, Belgium, The Netherlands, Czech Republic, Malaysia, Australia and New Zealand.
Tal marked the occasion with a lunch with some of the medical professionals involved in the PEARS project as well as members of the support team.
Tal Golesworthy spoke about PEARS at the fourth Slovenský Kardiochirurgický Kongres, which was held on 9 and 10 May in Demänovskej Doline, Slovakia. For more information about the conference, visit skchk.sk.
In an article published in the British Medical Journal, journalist Jacqui Thornton discusses the challenges faced by patients who invent new devices or treatments. The article features Tal Golesworthy and in describing the invention of the ExoVasc PEARS implant refers to him as the “ultimate patient innovator”. You can download the article here.